Bio Essence

Bio Essence LT Debt/Equity

The Long-Term Debt to Equity Ratio of Bio Essence (BIOE) as of Nov 5, 2026 is -0.03. In the previous year, Long-Term Debt to Equity Ratio was -0.02 — a change of 45.92% (lower).

LT Debt/Equity

-0.03

YoY

45.92%

Last updated:

Long-Term Debt to Equity Ratio of Bio Essence is 2025 -0.03 . Long-Term Debt to Equity Ratio of Bio Essence was 2024 -0.02 . It decreases by 45.92% lower compared to the previous year.

The Bio Essence LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2020
-0.12 USD
Jan 1, 2021
-0.10 USD
Jan 1, 2022
-0.07 USD
Jan 1, 2023
-0.12 USD
Jan 1, 2024
-0.02 USD
Jan 1, 2025
-0.03 USD
The Bio Essence LT Debt/Equity history
YEARLT Debt/EquityYoY
-0.03+45.92%
-0.02-84.56%
-0.12+65.07%
-0.07-28.98%
-0.10-14.14%
-0.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Essence Stock analysis

What does Bio Essence do? Bio Essence Corp. generates revenue through its three subsidiaries: Bio Essence Pharmaceutical (BEP), which operates as a health supplement original equipment manufacturer (OEM) service provider; Bio Essence Herbal Essentials (BEH), which targets healthcare practitioners with herbal products including granules, capsules, pills, and tablets, and offers special formulation services; and McBE Pharma (McBE), which develops, manufactures, and sells prescription drugs. The company's products are sold directly to healthcare practitioners such as dietitians and nutraceutical practitioners, who then recommend them to their patients. BEH specifically serves practitioners in the integrative healthcare market, providing both standard and custom-formulated herbal supplements. BEP functions as an OEM for health supplement manufacturers, producing private-label products under other brands. McBE Pharma focuses on prescription drugs, targeting healthcare providers for direct sales. The firm's direct connections with practitioners enable it to reach end consumers through professional recommendations rather than retail channels. Bio Essence Herbal Essentials Inc. (BEH) emphasizes its role in connecting practitioners with patients through tailored herbal supplement solutions. The company's revenue streams are derived from the sale of herbal health supplements, vitamin nutritional supplements, and prescription drugs. BEH's target segment includes practitioners who specialize in integrative healthcare, such as dietitians and nutraceutical practitioners, who use the company's products to support patient care. McBE Pharma's segment consists of healthcare providers seeking prescription drug solutions for their patients. BEP serves as a manufacturing partner for other supplement brands, supplying OEM services. Bio Essence is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Essence stock

Long-Term Debt to Equity Ratio of Bio Essence is -0.03 in 2025.

Long-Term Debt to Equity Ratio of Bio Essence changed from -0.02 to -0.03, representing a 45.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Bio Essence since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Bio Essence with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio Essence

All Key Metrics — Bio Essence